An estimated one in 10 people are affected by a rare disease, and the cumulative economic burden of rare diseases surpasses that of common conditions …
Warren Buffett’s Berkshire Hathaway doesn’t appear to be the oracle of every market movement, at least not in the case of an investment in Merck …
Drug development is an expensive, lengthy, and high-risk business taking 1015 years and is associated with a high attrition rate. Approximately only 1 in 10 …
Current and future cancer treatment is expected to be shaped and guided by the use of biomarkers that will guide researchers and physicians at every …
Despite spiralling drug development costs and timelines spawning industry-wide efficiency drives, tackling the multibillion-dollar problem of adherence has remained an untapped opportunity – until now. …
Seoul ranks first in the world in number of clinical trials per city. It is meaningful that the city shows a significant gap with Houston …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
